Pharma-Tech is an Egyptian joint stock company established in 2006.Here at Pharma-Tech we inspire for good health and better quality of life by offering a wide range of carefully selected products that will help millions of people live their lives better and healthier.we aim to touch people lives not just in Egypt but also in Middle East, Africa, and Europe. We will be involved in different therapeutic areas to help challenge the most feared diseases of our time like Osteoporosis, hyperprolactinemia, and hepatitis. At pharma-Tech we believe in the concept of “pain free hospitals” that’s why we will be offering different products in pain management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

INDEGENE PARTNERS WITH AMWELL TO EMPOWER LIFE SCIENCES ORGANIZATIONS WITH UNPARALLELED PATIENT SUPPORT SOLUTIONS

Indegene Inc | June 29, 2022

news image

Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes. Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are ava...

Read More

BUSINESS INSIGHTS

ASAHI KASEI BIOPROCESS TO SHOWCASE AWARD-WINNING MOTIV™ BUFFER MANAGEMENT TECHNOLOGY FOR PHARMACEUTICAL MANUFACTURING AT ACHEMA 2022

Asahi Kasei Bioprocess | August 01, 2022

news image

Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt this August. Winner of “Best in Show” at Interphex in 2017, “Technology of the Decade” from Bioprocess international in 2012 and originator of the concept for inline buffer formulation (IBF™), Asahi Kasei Bioprocess is a market leader that keeps pharmaceutical production mo...

Read More

PHARMA TECH

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Iktos | December 09, 2021

news image

Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to ...

Read More

BUSINESS INSIGHTS

STANDIGM NAMES CARL FOSTER CHIEF BUSINESS OFFICER TO EXPAND STRATEGIC PARTNERSHIPS FOR AI DRUG DISCOVERY

Standigm | August 19, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications. "Carl has established a reputation for increasing company value. He has significant experience building and growing biotech ...

Read More
news image

BUSINESS INSIGHTS

INDEGENE PARTNERS WITH AMWELL TO EMPOWER LIFE SCIENCES ORGANIZATIONS WITH UNPARALLELED PATIENT SUPPORT SOLUTIONS

Indegene Inc | June 29, 2022

Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes. Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are ava...

Read More
news image

BUSINESS INSIGHTS

ASAHI KASEI BIOPROCESS TO SHOWCASE AWARD-WINNING MOTIV™ BUFFER MANAGEMENT TECHNOLOGY FOR PHARMACEUTICAL MANUFACTURING AT ACHEMA 2022

Asahi Kasei Bioprocess | August 01, 2022

Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt this August. Winner of “Best in Show” at Interphex in 2017, “Technology of the Decade” from Bioprocess international in 2012 and originator of the concept for inline buffer formulation (IBF™), Asahi Kasei Bioprocess is a market leader that keeps pharmaceutical production mo...

Read More
news image

PHARMA TECH

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Iktos | December 09, 2021

Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to ...

Read More
news image

BUSINESS INSIGHTS

STANDIGM NAMES CARL FOSTER CHIEF BUSINESS OFFICER TO EXPAND STRATEGIC PARTNERSHIPS FOR AI DRUG DISCOVERY

Standigm | August 19, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications. "Carl has established a reputation for increasing company value. He has significant experience building and growing biotech ...

Read More